

Bevacizumab Biosimilar-Europe Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/B26D02B9AA3EN.html

Date: November 2017 Pages: 133 Price: US\$ 3,480.00 (Single User License) ID: B26D02B9AA3EN

Abstracts

Report Summary

Bevacizumab Biosimilar-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bevacizumab Biosimilar industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Bevacizumab Biosimilar 2013-2017, and development forecast 2018-2023 Main market players of Bevacizumab Biosimilar in Europe, with company and product introduction, position in the Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges

The report segments the Europe Bevacizumab Biosimilar market as:

Europe Bevacizumab Biosimilar Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)

Germany United Kingdom France Italy



Spain

Benelux Russia

Europe Bevacizumab Biosimilar Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

100mg 400mg

Europe Bevacizumab Biosimilar Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Colorectal cancer Lung cancer Breast cancer Renal cancers Brain cancers

Europe Bevacizumab Biosimilar Market: Players Segment Analysis (Company and Product introduction, Bevacizumab Biosimilar Sales Volume, Revenue, Price and Gross Margin):

Pfizer Allergan Amgen Biocon Reliance lifesciences Bevacizumab Beaconpharma Celgene Corporation Fujifilm Kyowa Kirin Biologics Hetero Drugs

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF BEVACIZUMAB BIOSIMILAR

- 1.1 Definition of Bevacizumab Biosimilar in This Report
- 1.2 Commercial Types of Bevacizumab Biosimilar
- 1.2.1 100mg
- 1.2.2 400mg
- 1.3 Downstream Application of Bevacizumab Biosimilar
- 1.3.1 Colorectal cancer
- 1.3.2 Lung cancer
- 1.3.3 Breast cancer
- 1.3.4 Renal cancers
- 1.3.5 Brain cancers
- 1.4 Development History of Bevacizumab Biosimilar
- 1.5 Market Status and Trend of Bevacizumab Biosimilar 2013-2023
 - 1.5.1 Europe Bevacizumab Biosimilar Market Status and Trend 2013-2023
 - 1.5.2 Regional Bevacizumab Biosimilar Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Bevacizumab Biosimilar in Europe 2013-2017
2.2 Consumption Market of Bevacizumab Biosimilar in Europe by Regions
2.2.1 Consumption Volume of Bevacizumab Biosimilar in Europe by Regions
2.2.2 Revenue of Bevacizumab Biosimilar in Europe by Regions
2.3 Market Analysis of Bevacizumab Biosimilar in Europe by Regions
2.3.1 Market Analysis of Bevacizumab Biosimilar in Germany 2013-2017
2.3.2 Market Analysis of Bevacizumab Biosimilar in United Kingdom 2013-2017
2.3.3 Market Analysis of Bevacizumab Biosimilar in France 2013-2017
2.3.4 Market Analysis of Bevacizumab Biosimilar in Italy 2013-2017
2.3.5 Market Analysis of Bevacizumab Biosimilar in Spain 2013-2017
2.3.6 Market Analysis of Bevacizumab Biosimilar in Benelux 2013-2017
2.3.7 Market Analysis of Bevacizumab Biosimilar in Russia 2013-2017
2.4 Market Development Forecast of Bevacizumab Biosimilar in Europe 2018-2023
2.4.2 Market Development Forecast of Bevacizumab Biosimilar in Spain 2013-2017

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES



- 3.1 Whole Europe Market Status by Types
- 3.1.1 Consumption Volume of Bevacizumab Biosimilar in Europe by Types
- 3.1.2 Revenue of Bevacizumab Biosimilar in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
- 3.2.1 Market Status by Types in Germany
- 3.2.2 Market Status by Types in United Kingdom
- 3.2.3 Market Status by Types in France
- 3.2.4 Market Status by Types in Italy
- 3.2.5 Market Status by Types in Spain
- 3.2.6 Market Status by Types in Benelux
- 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Bevacizumab Biosimilar in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Bevacizumab Biosimilar in Europe by Downstream Industry
- 4.2 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Major Countries

4.2.1 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Germany

4.2.2 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in United Kingdom

- 4.2.3 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in France
- 4.2.4 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Italy
- 4.2.5 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Spain
- 4.2.6 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Benelux
- 4.2.7 Demand Volume of Bevacizumab Biosimilar by Downstream Industry in Russia
- 4.3 Market Forecast of Bevacizumab Biosimilar in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BEVACIZUMAB BIOSIMILAR

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Bevacizumab Biosimilar Downstream Industry Situation and Trend Overview

CHAPTER 6 BEVACIZUMAB BIOSIMILAR MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE



- 6.1 Sales Volume of Bevacizumab Biosimilar in Europe by Major Players
- 6.2 Revenue of Bevacizumab Biosimilar in Europe by Major Players
- 6.3 Basic Information of Bevacizumab Biosimilar by Major Players

6.3.1 Headquarters Location and Established Time of Bevacizumab Biosimilar Major Players

6.3.2 Employees and Revenue Level of Bevacizumab Biosimilar Major Players6.4 Market Competition News and Trend

- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 BEVACIZUMAB BIOSIMILAR MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Pfizer

- 7.1.1 Company profile
- 7.1.2 Representative Bevacizumab Biosimilar Product
- 7.1.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Pfizer
- 7.2 Allergan
 - 7.2.1 Company profile
 - 7.2.2 Representative Bevacizumab Biosimilar Product
- 7.2.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Allergan

7.3 Amgen

- 7.3.1 Company profile
- 7.3.2 Representative Bevacizumab Biosimilar Product
- 7.3.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Amgen
- 7.4 Biocon
 - 7.4.1 Company profile
 - 7.4.2 Representative Bevacizumab Biosimilar Product
- 7.4.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Biocon
- 7.5 Reliance lifesciences
 - 7.5.1 Company profile
 - 7.5.2 Representative Bevacizumab Biosimilar Product
- 7.5.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Reliance lifesciences

7.6 Bevacizumab

- 7.6.1 Company profile
- 7.6.2 Representative Bevacizumab Biosimilar Product
- 7.6.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of



Bevacizumab

- 7.7 Beaconpharma
- 7.7.1 Company profile
- 7.7.2 Representative Bevacizumab Biosimilar Product
- 7.7.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of

Beaconpharma

7.8 Celgene Corporation

- 7.8.1 Company profile
- 7.8.2 Representative Bevacizumab Biosimilar Product
- 7.8.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.9 Fujifilm Kyowa Kirin Biologics
- 7.9.1 Company profile
- 7.9.2 Representative Bevacizumab Biosimilar Product
- 7.9.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Fujifilm

Kyowa Kirin Biologics

7.10 Hetero Drugs

- 7.10.1 Company profile
- 7.10.2 Representative Bevacizumab Biosimilar Product
- 7.10.3 Bevacizumab Biosimilar Sales, Revenue, Price and Gross Margin of Hetero Drugs

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BEVACIZUMAB BIOSIMILAR

- 8.1 Industry Chain of Bevacizumab Biosimilar
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BEVACIZUMAB BIOSIMILAR

- 9.1 Cost Structure Analysis of Bevacizumab Biosimilar
- 9.2 Raw Materials Cost Analysis of Bevacizumab Biosimilar
- 9.3 Labor Cost Analysis of Bevacizumab Biosimilar
- 9.4 Manufacturing Expenses Analysis of Bevacizumab Biosimilar

CHAPTER 10 MARKETING STATUS ANALYSIS OF BEVACIZUMAB BIOSIMILAR



- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Bevacizumab Biosimilar-Europe Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/B26D02B9AA3EN.html</u>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/B26D02B9AA3EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970